Magnetic Microspheres: A Model System for Site Specific Drug Delivery in Vivo

Widder, Kenneth J.; Senyei, Andrew E.; Scarpelli, Dante G.

doi:10.3181/00379727-158-40158

Cited by 414 publications

(185 citation statements)

References 0 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…[616] Three years later, Widder et al reported the delivery of doxorubicin anticancer drugs encapsulated within magnetic albumin microspheres. [617] In addition, MDT strategy was developed by several authors in the 1980s to use magnetic microspheres and microcapsules to deliver different drugs. [618] There were significant growths in the 1990s when 90Y beta-emitter radiotherapeutics were loaded on poly(lactic acid) coated magnetite microspheres and applied to subcutaneous tumors.…”

Section: Magnetic Drug Targetingmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

192

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

Section: Magnetic Drug Targetingmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

192

171

View full text Add to dashboard Cite

show abstract

“…On the other hand, microspheres with a diameter of 1 gim, when injected intravenously, filter through the lungs and become lodged in the liver. Microspheres may also be rendered site specific through the incorporation of particles of Fe3O4, which make them responsive to an externally placed magnet (25). The biodegradability and rate of clearance of microspheres after entrapment can likewise be controlled by their "hardness," which depends on the manner in which the microspheres have been prepared (2,26).…”

Section: Synthesis and Inhibitory Activity Of Inhibitor-bound Microspmentioning

confidence: 99%

Albumin microspheres as carrier of an inhibitor of leukocyte elastase: potential therapeutic agent for emphysema.

Martodam¹,

Twumasi²,

Liener³

et al. 1979

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Methods are described for the covalent attachment of succinoyl-Ala-Ala-Pro-ValCH2Cl, an active sitedirected inhibitor of human leukocyte elastase (EC 3.4.21.11), to microspheres of human albumin. (EC 3.4.21.11), an enzyme that has been implicated in lung tissue injury resulting in the development of emphysema (6, 7). Although these inhibitors would appear to offer promise for the treatment of emphysema, their therapeutic effectiveness would be considerably enhanced if they could be targeted directly to the lungs. As a step in this direction we report here the manner in which the succinoyl peptide chloromethyl ketone (SPCK) succinoyl (Suc)-AlaAla-Pro-ValCH2Cl, which has been shown to be one of the more potent inhibitors of human leukocyte elastase (5), may be covalently attached to HAM with the retention of significant inhibitory activity towards this enzyme. Also reported here are the results of preliminary experiments in vio that show that the carrier-borne inhibitor is in fact targeted primarily to the lungs, where about half of the injected dose has a half-life of approximately 17 days. (8) and is currently available in kit form as a carrier of radioactive tracers for diagnostic lung scanning (2-4), circulatory studies (9), and cardiac output (10). SPCK was synthesized as described (5). Ethylenediamine, 5,5'-dithiobis-(2-nitrobenzoic acid), and hexanediamine were purchased from Aldrich; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-acetylglycine from Sigma; ethyleneimine from Pierce; N-acetyl-DL-homocysteine thiolactone from Schwarz/Mann; and iodo[1-'4C]acetic acid and Na125I (carrier-free) from New England Nuclear. All other chemicals were reagent grade available from commercial sources. All aqueous reagents which were used during the course of the derivatization of HAM contained 0.025% Pluronic F-68 (BASF, Wyandotte, MI) in order to prevent the adherence of microspheres to the sides of reaction vessels and to facilitate uniform suspension. MATERIALS AND METHODSThe sequence of reactions involved in the covalent attachment of SPCK to HAM with extended side chains is described in detail in the legend accompanying Fig. 1. Briefly, the exposed carboxyl groups of HAM were first aminoethylated (step 1), and the amino groups so introduced (I), plus any amino groups already exposed on the surface of HAM, were thiolated with N-acetyl-DL-homocysteine thiolactone (step 2). The thiolated derivative (II) was again aminoethylated with ethyleneimine (step 3) to give the amino derivative (III), or with iodoacetate (step 4) to give the carboxyl derivative (IV). The side chain of IV could be further elongated by condensation with hexanediamine (step 5), yielding V. By virtue of the succinoyl group at the NH2 terminus of the peptide, the latter could be condensed with the amino groups of I, III, and V (step 6), thus yielding HAM-inhibitor derivatives denoted as Ii, IIIi, and Vi, respectively.Assay for Enzyme Activity. Human leukocyte elastase was prepared from purulent sputum as described (12) Step 1: 1...

show abstract

“…In 1978, magnetic particles were first applied as a new class of drug target (Widder et al, 1978). The superparamagnetic properties of the magnetic micro-and nanoparticles have opened promising new perspectives for in vivo application.…”

Section: Ionic Binding Of the Drug To The Magnetic Nanoparticlesmentioning

confidence: 99%

The Development of Magnetic Drug Delivery and Disposition

Marszałł¹

2012

The Delivery of Nanoparticles

View full text Add to dashboard Cite

Magnetic Microspheres: A Model System for Site Specific Drug Delivery in Vivo

Cited by 414 publications

References 0 publications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Albumin microspheres as carrier of an inhibitor of leukocyte elastase: potential therapeutic agent for emphysema.

The Development of Magnetic Drug Delivery and Disposition

Contact Info

Product

Resources

About